We are rapidly building a robust pipeline of AXA candidates with our platform. Our innovative paradigm integrates preclinical and Non-IND Clinical Studies* to understand the impact of AXA candidates on human biology.

This fast and capital efficient, iterative process has the potential to generate drug or consumer health product candidates with a higher probability of success in the development process.

Our innovative phenotypic approach to AXA candidate design includes:

  • Elucidating multifactorial disease pathway biology

  • Utilizing bioinformatics to rationally design AXA candidates from our libraries of amino acid biochemistry

  • Optimizing AXA candidates for administration amounts and distribution in multiple in vivo and in vitro models

  • Validating biology hypothesis

Our platform has produced a rich pipeline of AXA candidates with programs in liver, muscle, and CNS among other target areas.
 

*Axcella conducts Non-IND, IRB-approved food studies to evaluate the safety and tolerability of its AXA candidates in human subjects, or effects on the normal structure or function of the body. Studies intended to directly support drug development will be conducted under an IND.